Therefore, efforts should focus on gaining a better understanding of the contribution of p38 to the development of cancer and other diseases, both at the cellular and organismal level, to develop better compounds that specifically target the different components of this MAPK signaling pathway to improve responses to treatment and reduce the drawbacks of conventional inhibitors. This evidence concerns the gene MAPK1 and cancer.